NRG1

Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression

Retrieved on: 
Tuesday, March 5, 2024

The abstract describes Zeno’s activity in preclinical models representing different tumor types expressing high neuregulin 1 (NRG1) levels.

Key Points: 
  • The abstract describes Zeno’s activity in preclinical models representing different tumor types expressing high neuregulin 1 (NRG1) levels.
  • High NRG1 expression is associated with poorer prognosis in certain cancers and resistance to standard therapies.
  • The anti-tumor efficacy of Zeno in vivo against a panel of 28 patient-derived xenograft (PDX) models representing different tumor types was examined.
  • Title: Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective in cancer models with high NRG1 expression.

Non-Small-Cell Lung Cancer (NSCLC) Pipeline Landscape Report 2024: Comprehensive Insights About 100+ Companies and 120+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 6, 2024

This report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape.
  • A detailed picture of the Non-Small-Cell Lung cancer (NSCLC) pipeline landscape is provided which includes the disease overview and Non-Small-Cell Lung cancer (NSCLC) treatment guidelines.
  • The assessment part of the report embraces, in depth Non-Small-Cell Lung cancer (NSCLC) commercial assessment and clinical assessment of the pipeline products under development.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Non-Small-Cell Lung cancer (NSCLC) R&D.

Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023

Retrieved on: 
Sunday, November 26, 2023

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 26, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of two abstracts regarding MCLA-129 on the European Society for Medical Oncology (ESMO) Asia Congress website. The abstracts highlight updated interim clinical data from expansion cohorts in non-small cell lung cancer (NSCLC) and in previously treated head and neck squamous cell carcinoma (HNSCC) for presentation at the ESMO Asia Congress 2023 taking place in Singapore December 1-3, 2023.

Key Points: 
  • ET
    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 26, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of two abstracts regarding MCLA-129 on the European Society for Medical Oncology (ESMO) Asia Congress website.
  • The abstracts highlight updated interim clinical data from expansion cohorts in non-small cell lung cancer (NSCLC) and in previously treated head and neck squamous cell carcinoma (HNSCC) for presentation at the ESMO Asia Congress 2023 taking place in Singapore December 1-3, 2023.
  • Updated clinical data, with additional patients and a later data cutoff date, will be included in the mini-oral presentation on NSCLC and the poster on HNSCC at ESMO Asia next week.
  • An abstract for an encore of a recent ESMO Congress 2023 presentation on zenocutuzumab interim clinical data from the eNRGy trial and Early Access Program in patients with NRG1 fusion (NRG1+) NSCLC has also been accepted for presentation at ESMO Asia.

Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update

Retrieved on: 
Thursday, November 2, 2023

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the third quarter and provided a business update.

Key Points: 
  • In the planned trial, patients will be randomized to petosemtamab monotherapy or investigators’ choice of single agent chemotherapy or cetuximab.
  • Merus also continues to enroll patients with previously untreated advanced PD-L1+ HNSCC with petosemtamab 1500 mg in combination with Keytruda®.
  • Initial safety data from this single arm cohort may support the initiation of a first-line registration trial with this combination.
  • Merus achieved a milestone and received a payment of $2.5 million related to the advancement of this program in the third quarter of 2023.

Merus’ Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer

Retrieved on: 
Monday, October 23, 2023

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced interim clinical data, as of a July 31, 2023 data cutoff date, from the phase 1/2 eNRGy trial and Early Access Program (EAP) of the bispecific antibody zenocutuzumab (Zeno) in patients with neuregulin 1 fusion (NRG1+) cancer presented by Principal Investigator, Dr. Alison Schram* of Memorial Sloan Kettering Cancer Center at the European Society for Medical Oncology (ESMO) Congress 2023.

Key Points: 
  • “I’ve been impressed by the consistency of the Zeno clinical data and am convinced Zeno has the potential to be both a first and best in class treatment for NRG1+ cancer,” said Dr. Andrew Joe, Chief Medical Officer at Merus.
  • With Zeno’s durable efficacy and excellent safety profile reported at ESMO, I believe Zeno could be an important, new standard of care for patients with NRG1+ cancer.”
    The reported data are from the phase 1/2 eNRGy trial and EAP which are assessing the safety and anti-tumor activity of Zeno monotherapy in NRG1+ cancer.
  • Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
    Observations in the presentation include:
    As of July 31, 2023 data cutoff date, 105 patients with NRG1+ NSCLC were treated with Zeno.
  • Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)
    Observations in the presentation include:
    As of July 31, 2023 data cutoff date, 44 patients with NRG1+ PDAC were treated with Zeno.

Endeavor BioMedicines Enters License Agreement with Hummingbird Bioscience for Worldwide Rights to HMBD-501, a Next Generation HER3-Targeted Antibody-Drug Conjugate (ADC)

Retrieved on: 
Thursday, October 19, 2023

Hummingbird Bioscience (“Hummingbird Bio”), a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, and Endeavor BioMedicines (“Endeavor”), a clinical-stage company targeting the drivers of fibrosis and oncology, today announced that Endeavor has acquired exclusive worldwide rights to Hummingbird Bio’s antibody-drug conjugate (ADC), HMBD-501.

Key Points: 
  • Hummingbird Bioscience (“Hummingbird Bio”), a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, and Endeavor BioMedicines (“Endeavor”), a clinical-stage company targeting the drivers of fibrosis and oncology, today announced that Endeavor has acquired exclusive worldwide rights to Hummingbird Bio’s antibody-drug conjugate (ADC), HMBD-501.
  • The license agreement provides Endeavor with exclusive rights to HMBD-501, a next-generation HER3-targeted ADC with an exatecan payload that has been optimized for safety and efficacy.
  • Under the terms of the license, Hummingbird Bio will be eligible to receive upfront and milestone payments up to $430 million, plus royalties on net sales.
  • “We are pleased to license HMBD-501 to the experienced Endeavor team to bring the molecule into the clinic and a step closer to benefiting patients.”

Hummingbird Bioscience Announces Positive Phase I Clinical Data for HMBD-001 Monotherapy Trial at the European Society for Medical Oncology Congress 2023

Retrieved on: 
Monday, October 23, 2023

The trial is evaluating HMBD-001 as a monotherapy across various tumor types in the UK.

Key Points: 
  • The trial is evaluating HMBD-001 as a monotherapy across various tumor types in the UK.
  • As of the data cut-off on 8 September 2023, the trial had enrolled 23 heavily pre-treated patients across various tumor types where HER3 may play an important role.
  • The dose escalation trial cleared six monotherapy cohorts with no dose-limiting toxicities (DLTs) and there were no treatment discontinuations due to related adverse events.
  • " The Phase I/IIa clinical trial in the UK is sponsored and managed by Cancer Research UK's Centre for Drug Development.

Hummingbird Bioscience Announces Positive Phase I Clinical Data for HMBD-001 Monotherapy Trial at the European Society for Medical Oncology Congress 2023

Retrieved on: 
Monday, October 23, 2023

The trial is evaluating HMBD-001 as a monotherapy across various tumor types in the UK.

Key Points: 
  • The trial is evaluating HMBD-001 as a monotherapy across various tumor types in the UK.
  • As of the data cut-off on 8 September 2023, the trial had enrolled 23 heavily pre-treated patients across various tumor types where HER3 may play an important role.
  • The dose escalation trial cleared six monotherapy cohorts with no dose-limiting toxicities (DLTs) and there were no treatment discontinuations due to related adverse events.
  • " The Phase I/IIa clinical trial in the UK is sponsored and managed by Cancer Research UK's Centre for Drug Development.

Endeavor BioMedicines Enters License Agreement with Hummingbird Bioscience for Worldwide Rights to HMBD-501, a Next Generation HER3-Targeted Antibody-Drug Conjugate (ADC)

Retrieved on: 
Thursday, October 19, 2023

SAN DIEGO, HOUSTON and SINGAPORE, Oct. 19, 2023 /PRNewswire/ -- Hummingbird Bioscience ("Hummingbird Bio"), a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, and Endeavor BioMedicines ("Endeavor"), a clinical-stage company targeting the drivers of fibrosis and oncology, today announced that Endeavor has acquired exclusive worldwide rights to Hummingbird Bio's antibody-drug conjugate (ADC), HMBD-501.

Key Points: 
  • The license agreement provides Endeavor with exclusive rights to HMBD-501, a next-generation HER3-targeted ADC with an exatecan payload that has been optimized for safety and efficacy.
  • Under the terms of the license, Hummingbird Bio will be eligible to receive upfront and milestone payments up to $430 million, plus royalties on net sales.
  • This next generation ADC has the potential to address significant unmet clinical needs in areas left behind by HER2 agents."
  • "We are pleased to license HMBD-501 to the experienced Endeavor team to bring the molecule into the clinic and a step closer to benefiting patients."

Merus Announces Business Update Conference Call

Retrieved on: 
Monday, October 16, 2023

ET

Key Points: 
  • ET
    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 15, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that it will host a conference call to discuss a business update on Monday, October 16, 2023 at 7:30 a.m.
  • Merus also continues to enroll patients with previously untreated advanced PD-L1+ HNSCC with petosemtamab 1500 mg in combination with Keytruda®.
  • Merus plans to report initial interim safety and efficacy data from this cohort in the first half of 2024.
  • Merus will hold a conference call and webcast for investors on October 16, 2023 at 7:30 a.m.